Skip to main content

Table 1 Baseline Characteristics

From: Association between appropriateness of coronary revascularization and quality of life in patients with stable ischemic heart disease

Variable TOTAL N = 425 Appropriate N = 272 Inappropriate N = 57 Uncertain N = 96 P-value Medical N = 130 Revascularization N = 295 P-value
Age Mean ± SD 65.34 ± 10.86 66.04 ± 11.04 64.11 ± 10.90 64.09 ± 10.23 0.852 65.52 ± 11.69 65.26 ± 10.49 0.823
Male 79.1% 80.1% 78.9% 76.0% 0.123 84.6% 76.6% 0.155
Diabetes 35.1% 38.2% 21.1% 34.4% 0.047 36.9% 34.2% 0.593
Hypertension 74.8% 75.0% 73.7% 75.0% 0.475 80.8% 72.2% 0.152
Hyperlipidemia 89.9% 89.7% 89.5% 90.6% 0.443 90.8% 89.5% 0.764
Smoking 60.0% 62.1% 52.6% 58.3% 0.409 53.1% 3.1% 0.061
Symptom Severity         
CCS 0 19.8% 12.1% 40.4% 29..2% <0.001 23.1% 18.3% 0.029
CCS 1-2 48.9% 44.1% 59.6% 56.3%   54.6% 46.4%  
CCS 3-4 31.3% 43.8% 0% 14.6%   22.3% 35.3%  
LV ejection Fraction         
> = 60% 56.0% 54.4% 68.4% 53.1% 0.371 48.5% 59.3% 0.039
40-59% 21.9% 22.4% 14.0% 25.0%   30.0% 18.3%  
20-39% 9.4% 11.0% 8.8% 5.2%   10.0% 9.2%  
<=20% 0.7% 0.7% 0.0% 1.0%   1.5% 0.3%  
NA 12.0% 11.4% 8.8% 15.6%   10.0% 12.9%  
Coronary Anatomy         
1 -or 2 vessel CAD without involvement of proximal LAD 55.1% 40.8% 100.0% 68.8% <.001 63.8% 51.2% 0.016
Chronic total occlusion of 1 major epicaridial coronary artery without other coronary stenoses 0.5% 0.7% 0.0% 0.0% 0.568 0.0% 0.7% 0.347
1- vessel CAD involving the proximal LAD 8.0% 8.8% 0.0% 10.4% 0.051 4.6% 9.5% 0.088
2-vessel CAD involving the proximal LAD 4.7% 3.7% 0.0% 10.4% 0.005 4.6% 4.7% 0.953
3-vessel CAD (no left main) 18.8% 25.7% 0.0% 10.4% <.001 17.7% 19.3% 0.692
left main stenosis 13.4% 21.0% 0.0% 0.0% <.001 9.2% 15.3% 0.093
Previous CABG 16.7% 19.9% 1.8% 16.7% 0.005 28.5% 11.5% <.001
Previous CHF 6.4% 6.6% 3.5% 7.3% 0.74 12.3% 3.7% 0.003
Previous PCI 29.9% 29.4% 29.8% 31.3% 0.159 34.6% 27.8% 0.11
Prior MI 34.8% 33.8% 28.1% 41.7% 0.236 43.1% 31.2% 0.043
PVD 12.5% 11.8% 12.3% 14.6% 0.806 13.8% 11.9% 0.553
Creatinine Mean ± SD 95.92 ± 68.21 90.89 ± 23.96 94.46 ± 44.47 111.04 ± 132.88 0.221 106.38 ± 106.79 91.31 ± 40.45 0.971
Dialysis 1.4% 0.7% 1.8% 3.1% 0.227 2.3% 1.0% 0.299
Stroke 9.6% 9.9% 14.0% 6.3% 0.351 8.5% 10.2% 0.831
Dementia 0.7% 0.7% 0.0% 1.0% 0.341 0.8% 0.7% 0.102
Cancer 10.4% 11.8% 8.8% 7.3% 0.703 7.7% 11.5% 0.01
COPD 7.5% 8.8% 7.0% 4.2% 0.327 (4.6% 8.8% 0.131
Medications         
% on Maximal Anti-anginal Therapy 26.1% 32.0% 7.0% 20.8% <.001 20.8% 28.5% 0.096
ACE inhibitor/ARB 67.5% 66.9% 68.4% 68.8% 0.936 72.3% 65.4% 0.163
Statin 82.1% 83.1% 82.5% 79.2% 0.688 81.5% 82.4% 0.836
Β-Blocker 66.4% 68.8% 56.1% 65.6% 0.184 71.5% 64.1% 0.133
Treatment Strategy         
CABG 18.4% 21.7% 14.0% 11.5% 0.002 0.0% 26.4% <.001
Medical 30.6% 24.6% 47.4% 37.5%   130 100.0% 0.0%  
PCI 51.1% 53.7% 38.6% 51.0%   0.0% 73.6%  
Outcomes         
1- year Mortality 2.6% 2.6% 0.0% 4.2% 0.292 5.4% 1.4% 0.016
1-year Readmission for MI 9.9% 10.3% 7.0% 10.4% 0.738 5.4% 11.9% 0.039
1-year repeat PCI/CABG 10.4% 12.5% 3.5% 8.3% 0.098 5.4% 12.5% 0.026
  1. SD: standard deviation; CCS: Canadian Cardiovascular Society; LV: left ventricular; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; MI: myocardial infarction; PVD: peripheral vascular disease; COPD: chronic obstructive lung disease; CHF: Congestive heart failure; ARB: angiotensin receptor blocker.